Clinical Trials/JPRN-UMIN000011364

JPRN-UMIN000011364

Completed

Phase 2

Phase II study of FOLFIRI+biweekly cetuximab for KRAS wild type unresectable colorectal cancer. - Phase II study of FOLFIRI+biweekly cetuximab.

Osaka City University0 sites20 target enrollmentAugust 3, 2013

Conditionsunresectable colorectal cancer

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: unresectable colorectal cancer
Sponsor: Osaka City University
Enrollment: 20
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

August 3, 2013

End Date

TBD

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Osaka City University

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Phase IIstudy of biweekly FOLFIRI+cetuximab treatment for unresectable KRAS-wild type colorectal cancerunresectable colorectal cancer

JPRN-UMIN000011363Dept of Surgical Oncology Osaka City University Graduate School of Medicine20

Phase II study of FOLFIRI + cetuximab as induction chemotherapy followed by FOLFIRI + bevacizumab based on early tumor shrinkage in chemotherapy-naive patients with RAS wild-type colorectal cancerColorectal cancer

JPRN-UMIN000023026Department of Clinical Oncology, St. Marianna University School of Medicine54

Active, not recruiting

Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / Vadvanced colorectal carcinoma with wild type RAS and FcyRIIIA-V / VTherapeutic area: Diseases [C] - Cancer [C04]

EUCTR2018-003778-29-ITIstituto Nazionale Tumori G. Pascale34

Phase I study of FOLFOXIRI+cetuximab in patients with RAS wild-type unresectable colorectal cancerRAS wild-type unresectable colorectal cancer

JPRN-UMIN000015620Aichi Cancer Center Hospital12

Phase II trial of bi-weekly cetuximab plus mFOLFOX6 or cetuximab plus mFOLFIRI for unresectable advanced or recurrent KRAS wild type colorectal cancer (T-CORE1201)colorectal cancer

JPRN-UMIN000008298Tohoku Clinical Oncoogy, Research and Education Society(T-CORE)66